The impact of simvastatin on pulmonary effectors of Pseudomonas aeruginosa infection

PLoS One. 2014 Jul 10;9(7):e102200. doi: 10.1371/journal.pone.0102200. eCollection 2014.

Abstract

The statin family of cholesterol-lowering drugs is known to have pleiotropic properties which include anti-inflammatory and immunomodulatory effects. Statins exert their pleiotropic effects by altering expression of human immune regulators including pro-inflammatory cytokines. Previously we found that statins modulate virulence phenotypes of the human pathogen Pseudomonas aeruginosa, and sought to investigate if simvastatin could alter the host response to this organism in lung epithelial cells. Simvastatin increased the expression of the P. aeruginosa target genes KLF2, KLF6, IL-8 and CCL20. Furthermore, both simvastatin and P. aeruginosa induced alternative splicing of KLF6. The novel effect of simvastatin on wtKLF6 expression was found to be responsible for induction of the KLF6 regulated genes CCL20 and iNOS. Simvastatin also increased the adhesion of P. aeruginosa to host cells, without altering invasion or cytotoxicity. This study demonstrated that simvastatin had several novel effects on the pulmonary cellular immune response.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alternative Splicing / drug effects
  • Cell Line
  • Chemokine CCL20 / biosynthesis
  • Gene Expression Regulation / drug effects*
  • Humans
  • Immunity, Cellular / drug effects
  • Interleukin-8 / biosynthesis
  • Kruppel-Like Factor 6
  • Kruppel-Like Transcription Factors / biosynthesis
  • Lung / drug effects
  • Lung / immunology
  • Lung / pathology
  • Proto-Oncogene Proteins / biosynthesis
  • Pseudomonas Infections / drug therapy*
  • Pseudomonas Infections / genetics
  • Pseudomonas Infections / pathology
  • Pseudomonas aeruginosa / drug effects*
  • Pseudomonas aeruginosa / pathogenicity
  • Simvastatin / administration & dosage*

Substances

  • CCL20 protein, human
  • Chemokine CCL20
  • Interleukin-8
  • KLF2 protein, human
  • KLF6 protein, human
  • Kruppel-Like Factor 6
  • Kruppel-Like Transcription Factors
  • Proto-Oncogene Proteins
  • Simvastatin

Grants and funding

This research was supported in part by grants awarded by the European Commission (http://ec.europa.eu/index_en.htm)(FP7-PEOPLE-2013-ITN, 607786; FP7-KBBE-2012-6, CP-TP-312184; FP7-KBBE-2012-6, 311975; OCEAN 2011-2, 287589; Marie Curie 256596), Science Foundation Ireland (www.sfi.ie)(SSPC-2; 07/IN.1/B948; 12/TIDA/B2411; 12/TIDA/B2405; 09/RFP/BMT2350), the Department of Agriculture and Food (www.agriculture.gov.ie/) (FIRM/RSF/CoFoRD; FIRM 08/RDC/629), the Irish Research Council for Science, Engineering and Technology (www.research.ie/) (PD/2011/2414; RS/2010/2413), the Health Research Board (www.hrb.ie)(RP/2006/271; RP/2007/290; HRA/2009/146), the Environmental Protection Agency (www.epa.ie) (EPA2006-PhD-S-21; EPA2008-PhD-S-2), the Marine Institute (https://www.marine.ie) (Beaufort award C2CRA 2007/082) Teagasc (www.teagasc.ie) (Walsh Fellowship 2013), the Higher Education Authority of Ireland (www.hea.ie)(PRTLI4) and the Society For General Microbiology President's Fund for Research Visits (www.sgm.ac.uk). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.